


29. The compound of claim 1, having the formula:



30. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of any one of claims 1 to 29.

31. A method of treating cancer, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1 to 29.

32. A method of increasing EphA2 activity, said method comprising contacting an EphA2 protein with a compound of any one of claims 1 to 29.

33. A method of suppressing pro-oncogenic EphA2 activity, said method comprising contacting an EphA2 protein with a compound of any one of claims 1 to 29.

34. A method of reducing levels of EphA2, said method comprising contacting an EphA2 protein with a compound of any one of claims 1 to 29.

35. A method of inhibiting cancer cell migration and invasion, said method comprising contacting an EphA2 protein with a compound of any one of claims 1 to 29.

36. A method of selectively delivering a chemotherapeutic agent to EphA2 expressing cancer cells, said method comprising contacting an EphA2 protein with a compound of any one of claims 1 to 29, wherein R¹⁴ comprises a drug moiety.

* * * * *